NIH launched last phase 3 clinical trial to evaluate safety and effectiveness of blood thinners in adults with COVID-19
On Mar. 8, 2021, the NIH announced that it had launched the last of three phase 3 clinical…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
Baxter and Moderna announced agreement for manufacturing of Moderna COVID-19 vaccine in the US
On Mar. 8, 2021, Baxter and Moderna announced that they had entered into an agreement for Baxter BioPharma…
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
Moderna announced supply agreement to provide 13 million doses of COVID-19 vaccine to the Philippines
On Mar. 6, 2021, Moderna announced a supply agreement with the Government of the Philippines for 13 million…
Biotechnology | COVID-19 | Diagnostics | FDA
Adaptive Biotechnologies announced FDA EUA for T-Detect COVID to confirm prior COVID-19 infection
On Mar. 5, 2020, Adaptive Biotechnologies announced that the U.S. Food and Drug Administration (FDA) had issued an…
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackﾒs Phase 2a randomized, double-blind, placebo-controlled…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
FDA authorized Cue Health’s COVID-19 test for at-mome and Over The Counter Use
On Mar. 5, 2021, Cue Health announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021, Moderna announced that Takeda Pharmaceutical submitted a New Drug Application (NDA) to the Government…
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
Washington State Department of Health provided next-generation genome sequencing
On Mar. 4, 2021, the Washington State Department of Health announced contracts with virology labs at the University…
CureVac and Novartis signed initial agreement on manufacturing of COVID-19 vaccine candidate, CVnCoV
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacﾒs COVID-19 vaccine…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxﾙ (heat stable COVID-19 vaccine program)…
Biotechnology | Disease | FDA
Luminex received FDA Emergency Use Authorization and CE Mark for expanded NxTAG panel test Including SARS-CoV-2
On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
Biotechnology | COVID-19 | FDA
Resverlogix published evidence of apabetalone’s beneficial effects on COVID-19
On Mar. 3, 2021, Resverlogix and QIMR Berghofer Medical Research Institute announced the publishing of an article providing…
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
Altasciences announced phase I research for COVID-19 pneumonia treatment
On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for…
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
Biotechnology | Disease | Neurology | NIH | Therapeutics
NIH invested in next iteration of public-private partnership to advance precision medicine for Alzheimer’s disease
On Mar. 2, 2021, the NIH announced it had launched the next version of the Accelerating Medicines Partnership…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
Cerecor announced postitive data in phase 2 clinical trial in patients hospitalized with COVID-19 ARDS
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…